(Q35134370)

English

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

P Chollet

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

P Schöffski

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

K Weigang-Köhler

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

J H M Schellens

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

H Cure

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

N Pavlidis

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

V Grünwald

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

R De Boer

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

J Wanders

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

P Fumoleau

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

EORTC Early Clinical Studies Group

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1264-1270

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors related to survival following resection for gastric carcinoma.Analysis of 903 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2'-tetrahydrofuryl)-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ocular Side Effects with 5-Fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900237-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00237-5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35134370&oldid=1979067372"